Literature DB >> 7503589

A novel human monoclonal antibody against cervical cancer: its immunoreactivity with normal tube and ovary and with ovarian tumor tissue.

T Nakanishi1, T Okamoto, A Nawa, T Suzuki, K Ino, Y Wakahara, N Horibe, S Goto, Y Tomoda.   

Abstract

1-1-2D, a novel human monoclonal antibody (MAb) raised against cervical cancer, was examined for its immunohistochemical reactivity with ovarian cancer. Six of 10 ovarian cancer cell lines showed positive staining, while 3 of 5 cervical cancer cell lines were positive. Among tumor tissues, 15 of 18 (83%) ovarian serous cystadenocarcinomas and 10 of 12 (83%) ovarian clear cell adenocarcinomas were positive. We also performed immunohistochemical staining of the same cancer specimens with OC 125 and compared their reactivity. The frequency of positivity was similar, but the reactivity of the two MAbs was different. 1-1-2D stained the apical surface of the glandular epithelial cells and secretory products of the gland. On the other hand, OC 125 stained the cytoplasm as well as the plasma membrane of the glandular epithelial cells. These results suggest that 1-1-2D MAb recognizes a different antigen from that recognized by OC 125.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7503589     DOI: 10.1007/bf00634489

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  17 in total

1.  Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.

Authors:  G P Sutton; F B Stehman; L H Einhorn; L M Roth; J A Blessing; C E Ehrlich
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544

2.  Differences in the mechanisms of production and release of SCC-Ag and CEA from an established uterine cervical carcinoma cell line (AMCC-1).

Authors:  H Yabushita; Y Nakagawa; K Sawaguchi; M Noguchi; M Ishihara
Journal:  Asia Oceania J Obstet Gynaecol       Date:  1988-12

3.  Production of heavy-chain class-switch variants of human monoclonal antibody by recombinant DNA technology.

Authors:  S Komori; N Yamasaki; M Shigeta; S Isojima; T Watanabe
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

4.  Clinical remission criteria for epithelial carcinoma of the ovary.

Authors:  Y Morikawa; M Kawai; T Kano; F Kikkawa; H Oguchi; N Nakashima; T Ishizuka; Y Furuhashi; S E Hattori; K Kuzuya
Journal:  Gynecol Oncol       Date:  1993-03       Impact factor: 5.482

5.  Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation.

Authors:  Y Kikuchi; I Kizawa; K Oomori; M Miyauchi; T Kita; M Sugita; Y Tenjin; K Kato
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

6.  Human monoclonal antibody [1-1-2D] against cancer of the uterine cervix.

Authors:  O Yamamuro; S Goto; H Mano; M Saito; M Watanabe; T Nagoya; Y Tomoda
Journal:  Hybridoma       Date:  1994-04

7.  The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer.

Authors:  J M Niloff; R C Knapp; P T Lavin; G D Malkasian; J S Berek; R Mortel; C Whitney; V R Zurawski; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1986-07       Impact factor: 8.661

8.  Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; R B Colvin
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

9.  Tumor markers for ovarian cancer. A comparative immunohistochemical and immunocytochemical study of two commercial monoclonal antibodies (OV632 and OC125).

Authors:  I A Koelma; M Nap; G J van Steenis; G J Fleuren
Journal:  Am J Clin Pathol       Date:  1988-10       Impact factor: 2.493

10.  Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer.

Authors:  S C Rubin; L Kostakoglu; C Divgi; M G Federici; C L Finstad; K O Lloyd; S M Larson; W J Hoskins
Journal:  Gynecol Oncol       Date:  1993-10       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.